|
gptkbp:instanceOf
|
gptkb:antiviral_drug
gptkb:chemical_compound
gptkb:antineoplastic_agent
|
|
gptkbp:approvalYear
|
1992
|
|
gptkbp:ATCCode
|
P01AX06
|
|
gptkbp:bioavailability
|
variable, increased with fatty food
|
|
gptkbp:brand
|
gptkb:Mepron
Malarone (with proguanil)
|
|
gptkbp:CASNumber
|
95233-18-4
|
|
gptkbp:chemicalFormula
|
C22H19ClO3
|
|
gptkbp:combines
|
gptkb:proguanil
|
|
gptkbp:contraindication
|
hypersensitivity to atovaquone
|
|
gptkbp:discoveredBy
|
GlaxoSmithKline
|
|
gptkbp:eliminationHalfLife
|
2–3 days
|
|
gptkbp:excretion
|
feces
|
|
gptkbp:IUPACName
|
2-[trans-4-(4-chlorophenyl)cyclohexyl]-3-hydroxy-1,4-naphthoquinone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits mitochondrial electron transport
|
|
gptkbp:meltingPoint
|
220–221 °C
|
|
gptkbp:metabolism
|
minimal
|
|
gptkbp:molecularWeight
|
366.84 g/mol
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
diarrhea
headache
rash
|
|
gptkbp:usedFor
|
treatment of malaria
treatment of Pneumocystis jirovecii pneumonia
treatment of toxoplasmosis
|
|
gptkbp:bfsParent
|
gptkb:Pneumocystis_pneumonia
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
atovaquone
|